Prosecution Insights
Last updated: August 18, 2026

Examiner: BYRD, BRIGID K

Tech Center 3700 • Art Units: 3771

This examiner grants 71% of resolved cases

Performance Statistics

71.2%
Allow Rate
+1.2% vs TC avg
363
Total Applications
+48.3%
Interview Lift
1020
Avg Prosecution Days
Based on 323 resolved cases, 2023–2026

Rejection Statute Breakdown

0.6%
§101 Eligibility
26.5%
§102 Novelty
39.1%
§103 Obviousness
28.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18925468 COUPLING PROXIMAL AND DISTAL PORTIONS OF A MEDICAL DEVICE Non-Final OA Boston Scientific Scimed, Inc.
18829096 OCCLUSIVE MEDICAL DEVICE WITH SEALING MEMBER Final Rejection BOSTON SCIENTIFIC SCIMED, INC.
18965997 Left Atrial Appendage Occluder Hook Placement Non-Final OA St. Jude Medical, Cardiology Division, Inc.
19433418 INTRAVASCULAR LITHOTRIPSY DEVICE Final Rejection IV-X Medical, LLC
19105668 MULTI-MODALITY BALLOON CATHETER INCLUDING LITHOTRIPSY BALLOON Non-Final OA Medtronic, Inc.
17609085 CONTINUOUS TETHERED TISSUE ANCHOR AND ASSOCIATED SYSTEMS AND METHODS Final Rejection W. L. Gore & Associates, Inc.
18847594 THROMBUS REMOVAL SYSTEMS AND ASSOCIATED METHODS Non-Final OA Shifamed Holdings, LLC
18910218 DELIVERY CATHETERS WITH ANTI-REFLUX OCCLUDER AND ANTI-STRETCH FEATURES Final Rejection Neuravi Limited
17838626 EXPANDABLE POLYMERIC FLARE TIP CATHETER AND METHODS OF FABRICATING SAME Final Rejection Neuravi Limited
18928315 NEGATIVE PRESSURE SUCTION SHEATH Final Rejection INNOVEX MEDICAL CO., LTD.
18839290 OPEN LOOP ÉCRASEUR FOR TENOTOMY Non-Final OA INCITE MEDICAL SARL
18038950 A Trephine Blade For Preparation Of Corneal Tissue For Endothelial Keratoplasty Non-Final OA CORZA MEDICAL, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month